Technology & Science
Mar. 3, 2010
MoFo Advises Astellas Pharma
Morrison & Foerster is advising Tokyo-based Astellas Pharma in a contentious bid to acquire New York-based OSI Pharmaceuticals in a deal valued at $3.5 billion.
Daily Journal Staff Writer
Morrison & Foerster is advising Tokyo-based Astellas Pharma in a contentious bid to acquire New York-based OSI Pharmaceuticals in a deal valued at $3.5 billion.
But OSI, a biotech company, focused on the development and marketing of drugs to treat cancer, diabetes and obesity, isn't jumping at the all-cash offer.
According to a press release issued Monday, OSI be...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In